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Abstract
Background: With an ageing population, older persons become a larger part of the hospital population. The incidence
of delirium is high in this group, and experiencing delirium has major short- and long-term sequelae, which makes
prevention crucial. During delirium, a disruption of the sleep-wake cycle is frequently observed. Melatonin plays an
important role in the regulation of the sleep-wake cycle, so this raised the hypothesis that alterations in the metabolism
of melatonin might play an important role in the development of delirium. The aim of this article is to describe the
design of a randomised, placebo controlled double-blind trial that is currently in progress and that investigates the
effects of melatonin versus placebo on delirium in older, postoperative hip fracture patients.
Methods/Design: Acutely hospitalised patients aged 65 years or older admitted for surgical repair of hip fracture are
randomised (n = 452) into a treatment or placebo group. Prophylactic treatment consists of orally administered
melatonin (3 mg) at 21:00 h on five consecutive days. The primary outcome is the occurrence of delirium, to be
diagnosed according to the Confusion Assessment Method, within eight days after start of the study medication.
Secondary outcomes are delirium severity, measured by the Delirium Rating Scale; duration of delirium; differences in
subtypes of delirium; differences in total length of hospital stay; total dose of antipsychotics and/or benzodiazepine use
during delirium; and in-hospital complications. In the twelve-month follow up visit, cognitive function is measured by a
Mini-Mental state examination and the Informant Questionnaire on Cognitive Decline in the Elderly. Functional status is
assessed with the Katz ADL index score (patient and family version) and grip strength measurement. The outcomes of
these assessments are compared to the outcomes that were obtained during admission.
Discussion: The proposed study will contribute to our knowledge because studies on the prophylactic treatment
of delirium with long term follow up remain scarce. The results may lead to a prophylactic treatment for frail older
persons at high risk for delirium that is safe, effective, and easily implementable in daily practice.
Trial registration: Dutch Clinical Trial Registry: NTR1576
Background
Delirium is the most frequent neuropsychiatric syndrome
observed in acutely admitted elderly patients in hospitals
a n di sa s s o c i a t e dw i t ha ni n c r e a s e dr i s ko fd e m e n t i a ,
mortality, and institutionalisation [1]. The incidence of
delirium varies depending on the methods employed and
the population studied but were shown to be 53% in a
former cohort of hip fracture patients studied by our
group [2]. Most clinical patients with delirium suffer
from pre-existing cognitive impairment based upon neu-
rodegenerative brain lesions. The prophylactic treatment
or early treatment of delirium may prevent these patients
from experiencing accelerated cognitive decline [3].
Thus, prevention is crucial.
The current prophylactic treatment of delirium consists
of both pharmacological treatment with antipsychotics
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ter seems the most effective [4]. Pharmacological treat-
ment with antipsychotics often leads to serious side
effects such as drowsiness and concomitant falls. In addi-
tion, up to a ten-fold increase in risk of cerebrovascular
accidents in the first week of treatment was found and a
higher frequency of prolonged QT-interval or extra pyra-
midal symptoms have been reported [5,6]. Given these
serious side effects, safer treatment options are war-
ranted. Recently, melatonin has been hypothesised to
play a part in delirium, both as a biomarker and as a safe
treatment option [7].
Melatonin, a hormone secreted by the pineal gland,
plays an important role in the regulation of the sleep-
wake cycle [8]. During delirium, disruption of the sleep-
wake cycle, such as fragmented sleep during the night
and sleepiness during the day, is frequently observed [9].
This trend raises the hypothesis that alterations in the
metabolism of melatonin may play an important role in
the development of delirium [10]. Elderly persons have
decreased peaks of nocturnal melatonin concentrations
[11]. Serum melatonin concentrations were also found to
be lower with later nocturnal peak concentrations in
elderly persons with insomnia as compared to age-
matched controls without insomnia [12]. Additionally, a
disturbed circadian pattern of melatonin secretion has
been found in post-operative patients with delirium [13].
In another study among medical patients, differences in
urinary melatonin metabolite concentrations were found
during delirium and after recovery from delirium [14].
These results may suggest an association between delir-
ium and a disturbed melatonin secretion pattern.
Investigations into the relationship between melatonin
therapy and delirium have also been undertaken. One
case report showed that exogenous administration of
melatonin prevented the occurrence of delirium [15].
There are indications that melatonin is effective in the
treatment of sleep-wake cycle disturbances in ICU
patients and in patients with dementia [16,17]. Moreover,
it has been demonstrated that treatment with melatonin
increases total sleeping time and reduced sleep latency in
elderly patients [18], and it enhances sleep time and
night activity in patients with Alzheimer’sd e m e n t i a[ 1 9 ] .
Recently, two randomised clinical trials on prophylactic
treatment with melatonin have been performed. Both
studies showed a reduction in the occurrence of delirium
in medical and elective surgical patients [20,21]. How-
ever, no follow up data were available, and the potential
of melatonin to prevent long term adverse events like
dementia still remains unclear.
This paper describes the design of the study; “The effects
of melatonin versus placebo on delirium in hip fracture
patients”, a trial currently in progress. The aims of the
study are to investigate whether prophylactic treatment
with melatonin will lead to a reduction in the occurrence
of delirium in hip fracture patients and to study whether




1] Is there a difference in the occurrence of delirium
within eight days of hospital admission between hip
fracture patients treated with melatonin or placebo?
Secondary outcome measures
2] Severity and duration of delirium.
3] Subtypes of delirium.
4] Length of hospital stay.
5] Additional use of benzodiazepines during delirium.
6] Total dose of haloperidol for the treatment of
delirium.
7] In-hospital complications.
8] Cognitive and functional decline twelve months
after hospital admission.
9] Mortality during hospital stay and twelve months
after hospital admission.
Study design
This study is a randomised, placebo-controlled, double
blind, national, multicentre study with a one-year prospec-
tive follow-up. Figure 1 shows the design of the study.
Informed consent is obtained from all patients or a legal
representative in the case of cognitive impairment. Over
five evenings, the patients receive the study medication
consisting of a tablet containing either a placebo or 3 mg
melatonin. Subsequently, daily assessment for the presence
of delirium is performed, and the patients are followed for
another three days. In total, each patient is observed for a
minimum of eight days. For patients who are not delirious
on day eight, daily assessments are stopped. For patients
who are delirious by day eight, to evaluate duration of
delirium, daily clinical assessments are continued until the
symptoms of delirium are resolved or until the patient is
discharged. Possible confounding factors including demo-
graphy, fracture characteristics, type of anaesthesia, type of
surgery and peri- and postoperative complications are
registered for all patients. This study is carried out in com-
pliance with the Helsinki Declaration. The Medical Ethics
Committee (METC) of the Academic Medical Centre
(AMC) has approved the study design, protocol and
informed consent procedures. The executive board of
Tergooihospitals has provided local feasibility approval.
Location and setting
The primary trial location is the surgical, orthopaedic or
trauma surgery ward of the AMC in Amsterdam, The
Netherlands. This is a major teaching hospital, containing
1002 beds. The secondary location is Tergooihospitals, a
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in Hilversum and Blaricum, The Netherlands.
Study population and recruitment
The study population consists of patients of 65 years
and older who are admitted for the surgical treatment
of hip fractures. Hip fractures are defined as fractures of
the femoral neck, the trochanteric region or the proxi-
mal femur. Further inclusion criteria are enrolment
within 24 hours of admission and the patient must be
willing and medically able to receive the study medica-
tion according to the protocol for the duration of the
study. Exclusion criteria are the inability to speak or
understand Dutch, the concomitant use of melatonin
and prior participation in this study.
Randomisation
A randomisation schedule, made by an independent sta-
tistician, is employed that is stratified by study centre
and uses block randomisation of ten participants per
block. The trial-pharmacist is the only one in possession
of the randomisation list.
Study medication
Study medication tablets all look the same and are pack-
aged in small pots labelled according to Good Manufactur-
ing Procedure (GMP) guidelines. The concentration is a
fixed concentration as both placebo and melatonin are
manufactured by and obtained from the same pharmaceu-
tical company. On prescription by SdR, AdJ or CvR, a pot
can be collected at the pharmacy when a patient is
included.
Data collection
Demographic data, medical history and medication use are
recorded. Once included in the study, patients are visited
daily (and once during the weekend) for efficacy and safety
evaluations by an experienced team of geriatric nurses and
geriatricians. For the diagnosis of delirium, the Cognitive
Assessment Method (CAM) is used [22,23]. The CAM
was developed in 1990 and is a validated and widely used
screening tool for the presence of delirium. When patients
are delirious, the severity of delirium is examined using
the Delirium Rating Scale-Revised-1998 (DRS-R-98). The
severity of delirium is expressed as the maximum DRS-R-
98 score during the delirium period. Subtyping is exam-
ined using the Delirium Symptom Interview [24] and the
Delirium Motoric Checklist [25]. Cognitive and functional
status and the presence of impairment prior to admission
are assessed. Each patient and their primary caregiver are
asked to complete questionnaires to assess the patient’s
pre-existent functional and cognitive state two weeks prior
to hospital admission. Functional status is assessed using
the 15-item Katz Activities of Daily Living (ADL) index
score, based on the situation two weeks prior to admis-
sion, to be completed by the patient or their closest rela-
tive in cases of cognitive impairment. Impairment is
calculated using the number of impaired ADLs [26].
Primary caregivers are asked to complete the Informant
Questionnaire on Cognitive Decline short form (IQCODE-
sf) [27] by recalling the situation two weeks prior to the
hip fracture and comparing this with the situation ten
years earlier. Patients with a mean score of 3.9 or higher
are considered to have global cognitive impairment [28].
Grip strength of the dominant hand, as an objective mea-
surement of functional status [29], is measured using
hand-held dynamometry. The severity and number of
comorbidities is scored using the Charlson comorbidity
index [30]. At the time of discharge from the hospital the
total amount of haloperidol and other antipsychotics used
during hospital admission is recorded, also the length of
stay and in-hospital complications are collected.
Follow-up assessments
Three months after admission, a home visit is made by a
trained nurse, to perform a Mini-Mental State Examina-
tion (MMSE) [31] and to measure the grip-strength of
the dominant hand. The MMSE is a validated 30-point
questionnaire-based test that is used to screen for cogni-
tive impairment. Twelve months after the hospital
admission, the patient is visited again at home by a
trained nurse to perform a MMSE test and a Katz ADL
index score and to assess grip-strength. Additionally, the
patient’s primary caregiver is asked to complete the
caregiver’s version of the Katz ADL index score and the
IQCODE-sf by telephone.
Delirium treatment
All patients receive ‘care as usual’, which means that if
postoperative delirium occurs, patients are treated
Admission
Screening based on in-




Placebo  Melatonin 3 mg
Follow-up at 3 months












Figure 1 Design of the RCT; inclusion of patients with hip
fracture, 65 years and older.
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ium severity and duration. Any underlying illness is
treated according to the hospital guidelines. If there is a
clinical diagnosis of hyperactive or mixed delirium,
treatment with anti-psychotics (most frequently with
haloperidol) is started according to a fixed scheme.
Daily adjustment of medication takes place depending
on the clinical judgement of the consulting geriatric
team and/or the attending physician. Antipsychotic
medication is standardiseda sm u c ha sp o s s i b l e ,w i t h
escape medication in cases of acute aggravation. Patients
on psychiatric medication, apart from their delirium
medication, can continue their prescriptions throughout
the study-period because melatonin does not interfere
with any other medication.
Power analysis
The primary endpoint is the occurrence of delirium during
the first eight days after the start of study medication. In
the AMC, the incidence of delirium in patients after surgi-
cal repair of hip fracture is now over 50% [2]. The preven-
tion of delirium has been previously assessed in several
studies. At the time this study began, other studies using
medication prophylaxis had not shown any significant
reduction in the incidence of delirium. Assuming an abso-
lute reduction of 13%, with a 50% incidence of delirium in
the control group and an incidence of 37% in the interven-
tion group, we require 226 patients per group (452
patients in total) to detect differences with a power of 80%
and a two-sided alpha of 0.05.
Statistics
Data will be primarily analysed according to the intention-
to-treat principle and secondarily compared by per proto-
col analysis. To study the effectiveness of the melatonin
treatment, the difference in the occurrence of delirium
between patients treated with or without melatonin will be
tested with Chi-square statistics. Continuous secondary
outcome measures, if normally distributed, will be tested
using a Students’ t-test, otherwise Mann-Whitney tests
will be employed. The duration of delirium will be tested
using a log-rank test. Categorical outcome variables will
be tested with a Chi-square test. Outcomes for patients
who had delirium at day one of the study will be calcu-
lated separately. Subsequently, multivariable logistic
regression will be used to compare differences between
melatonin and placebo groups in the primary and in the
secondary outcome measures.
Discussion
With an ageing population, older persons become a larger
part of the hospital population. Experiencing delirium has
major consequences for these patients’ outcomes following
hospital stay. From treatment trials with haloperidol, it
became known that once delirium exists, it is difficult to
influence its duration [32]. The prevention of delirium
should therefore be a main focus in the treatment of older
persons in hospital. To be able to adequately compare the
placebo versus melatonin intervention, we selected an
RCT-design. Because the proposed study is a prevention
trial, the primary measure is ‘occurrence of delirium’.W e
decided to enrol acutely admitted hip fracture patients
because they represent a homogeneous group with a high
incidence of delirium. To achieve good external validity,
we include patients with dementia as well because they are
especially prone to develop delirium. Therefore, the results
will be widely applicable to the general older hospital
population.
The proposed study will contribute to our knowledge
because studies on the prophylactic treatment of delir-
ium with follow up remain scarce. Our work may lead
to a prophylactic treatment for frail older persons at
high risk for delirium that is safe, effective, and easily
implementable in daily practice.
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